Tumour necrosis factor (TNF) induces apoptosis in a range of cell types via its two receptors, TNFR1 and TNFR2. Here, we demonstrate that proliferation and TNFR2 expression was increased in human leukaemic TF-1 cells by granulocyte macrophage-colony stimulating factor (GM-CSF) and interleukin-3 (IL-3), with TNFR1 expression unaffected. Consequently, they switch from a proliferative to a TNF-induced apoptotic phenotype. Raised TNFR2 expression and susceptibility to TNF-induced apoptosis was not a general effect of proliferation as IL-1b and IFN-c both proliferated TF-1 cells with no effect on TNFR expression or apoptosis. Although raised TNFR2 expression correlated with the apoptotic phenotype, stimulation of apoptosis in GM-CSF-pretreated cells was mediated by TNFR1, with stimulation of TNFR2 alone insufficient to initiate cell death. However, TNFR2 did play a role in apoptotic and proliferative responses as they were blocked by the presence of an antagonistic TNFR2 antibody. Additionally, coincubation with cycloheximide blocked the mitotic effects of GM-CSF or IL-3, allowing only the apoptotic responses of TNF to persist. TNF life/death was also observed in K562, but not MOLT-4 and HL-60 human leukaemic cell types. These findings show a cooperative role of TNFR2 in the TNF life/death switching phenomenon.
Introduction
Tumour necrosis factor-a (TNF) cytokine is produced mainly by activated macrophages and monocytes. 1 Although TNF was first recognised for its ability to induce haemorrhagic necrosis of certain tumours, 2 it also mediates a variety of other physiological responses, including differentiation, inflammation and proliferation as well as apoptotic and necrotic cell death. 3 TNF also produces the systemic effects of fever and cachexia. 4 TNF mediates its actions by binding to distinct cell surface receptor types, Tumour necrosis factor receptor (TNFR)1 (p55TNFR or CD120a) and TNFR2 (p75TNFR or CD120b), 5 and the existence of two receptor subtypes may partially explain the disparity of TNF-induced effects. 6 Human TNFR1 and TNFR2 extracellular domains share 28% identity, while there is a complete absence of homology between the intracellular domains of the two TNFRs. 7 The two receptor subtypes mediate their effects on cells through distinct signalling pathways. The relative surface expression of these two TNF receptors can affect the cellular responses to TNF stimulation and this can be altered by the growth state or metabolic activity of the cell. 5, 8 A variety of agents have been tested with regard to their ability to alter the level of TNFRs, and subsequently alter the effects of TNF. [9] [10] [11] [12] Apoptosis (programmed cell death) plays an important role in the homeostasis and development of all tissues within an organism. Apoptosis can be initiated by a variety of stimuli including growth factor withdrawal, ultraviolet-or g-irradiation and many chemotherapeutic drugs. 13 In contrast to necrosis, apoptosis is a well-regulated physiological process which is characterised by macromolecular breakdown and cellular fragmentation. 14 Fragmentation of apoptotic cells into membrane-bound apoptotic bodies and membrane changes eventually leads to phagocytosis of the affected cell. 15 TNF may act as a negative regulator of haematopoiesis to directly suppress proliferation by inducing apoptosis. 16 This effect is primarily mediated by signalling through TNFR1 17, 18 which is essential for regulating haematopoiesis. 19, 20 The majority of TNF-induced nuclear factor-kB (NF-kB) activation, 21 growth inhibition and suppression of proliferation also resulted exclusively from activation of TNFR1. 22 Although TNF has a cytotoxic or cytostatic effect when tested with various malignant cell lines, clinical trials in cancer patients have revealed high systemic toxicity of TNF. 23, 24 It is at present unclear which of the receptors are responsible for the various effects of TNF, although TNFR1 appears to be the predominant receptor that signals both cytotoxic and inflammatory responses. 25 Therefore, agents which act selectively on TNFR2 may be without some of the side effects of TNF in cancer treatment, which at present limit its effectiveness.
Granulocyte macrophage-colony stimulating factor (GM-CSF) and interleukin-3 (IL-3) are two haemopoietic growth factors that significantly contribute to the regulation of haemopoietic progenitor cell proliferation and differentiation. 26, 27 Previous studies using these cytokines, before and during chemotherapy to recruit leukaemia cells into cell cycle, and thus make them more susceptible to chemotherapy, have revealed no benefit. 28 However, with the findings that certain conditions can increase the expression of TNFR2, 8 this may represent a possible mechanism with which to increase susceptibility to TNF-induced apoptosis, while avoiding some of the deleterious side effects of TNF. In this study, we investigated the effects of cytokines on the levels of TNFR expression and the effect these cytokines have on the relative susceptibility of TF-1 cells to TNF-induced apoptosis. We compare the apoptotic and proliferative effects of agents selective in TNFR subtype activation, and report novel modulation and exchange between TNF-driven cytotoxicity or TNF-induced proliferation (TNF life/death switching).
Results
Cytokine control of TNF life/death switching of TF-1 cells
Our previous work on TF-1 cells uncovered a novel TNF life/ death switching phenomenon that see the same leukaemic cell switch from their normally proliferative state upon TNF treatment to a TNF-responsive apoptotic phenotype, dependent on the mitotic condition of the cell. 8 Here, we show that GM-CSF and IL-3 pretreatment can switch TF-1 cells from a TNF proliferative-to a TNF apoptotic phenotype. When GM-CSF or IL-3 was added to TF-1 cells, a large increase in total cell number was observed (Figure 1a ). TNF in itself is mildly proliferative too to normal TF-1 cell (Figure 1a ). This proliferative effect is seen in untreated cells, which respond to TNF by becoming mitotic (Figure 1b) . However, pretreatment of TF-1 cells with GM-CSF ( Figure 1b ) and IL-3 (not shown) switched these cells into an apoptotic phenotype when stimulated with TNF. Thus, the same cell responds to TNF with either proliferation or apoptosis, and which is brought about by GM-CSF and IL-3. Addition of TNF to proliferating TF-1 cells (precultured in GM-CSF-containing medium) caused a concentration-dependent increase in the number of cells in the hypodiploid region after propidium iodide staining (Figure 2a ) and an increase in Annexin-V binding to membrane-exposed phosphatidylserine (Figure 2b ) -both indicators of apoptosis -as well as the observed decrease in overall mitochondrial health, an indicator of cell viability and cell number measured by the MTS assay ( Figure 1b) .
In quiescent cells, TNF (10 ng/ml) caused a slight increase in apoptosis, whereas GM-CSF (0.1 ng/ml) and IL-3 (10 ng/ ml) were antiapoptotic (Figure 3a and b) . However, coincubation of cells with TNF and either GM-CSF or IL-3 increased TF-1 cell susceptibility to TNF-induced apoptosis (observed as an increase in the hypodiploid peak with propidium iodide staining). These observations were confirmed by an increase in the levels of poly(ADP-ribose) polymerase (PARP) fragment present in these apoptotic cells (Figure 3c and d) . PARP DNA repair enzyme is cleaved in a caspase-dependent manner and is a good indicator of apoptosis.
Role of TNFRs
TF-1 cells cultured in GM-CSF-free medium expressed similar levels of TNFR1 and TNFR2 (Figure 4a ). The surface expression of TNFR2 on TF-1 cells was increased by addition of GM-CSF or IL-3 to the culture media (Figures 4b and c) . Addition of both growth factors together had no additional increase above the individual effects (data not shown). Neither GM-CSF nor IL-3 -added alone or together -had any effect on the expression of TNFR1 (data not shown). Thus, the proliferative effects of GM-CSF and IL-3 lead to an increased expression of TNFR2, which may be responsible for the switching into an apoptotic phenotype rather than a (Figure 5d ). Thus, proliferation of TF-1 cells in itself is not sufficient to cause apoptotic effects of TNF, but requires increased expression of TNFR2 for the cytotoxic effects of TNF to become apparent. As the increased expression levels of TNFR2 could be responsible for the increased susceptibility to TNF-induce apoptosis, we examined the effects of the TNFR-selective muteins, R1-TNF and R2-TNF, which bind selectively to TNFR1 and TNFR2, respectively. In GM-CSF-pretreated TF-1 cells, R1-TNF caused a similar concentration-dependent increase in apoptosis and cytotoxicity to wild-type TNF, whereas R2-TNF had little or no effect on either apoptosis or toxicity of proliferating cells ( Figure 6 ). This is surprising given that TNFR1 expression remains unchanged, but increases in TNFR2 levels correlate with increased TNFinduced apoptosis. We also observed that addition of R1-TNF TNF 0 ng/ml 0.1 ng/ml 1 ng/ml 10 ng/ml TNF 0 ng/ml 0.1 ng/ml 1 ng/ml 10 ng/ml 100 ng/ml were: control -17.1%, 0.1 ng/ml GM-CSF -5.0%, 10 ng/ml IL-3 -4.5%, 10 ng/ml TNF -31.3%, GM-CSF þ TNF -49.4%, IL-3 þ TNF -48.7%. Cells in the M1 region for (c) and (d) were: control -62.8%, 0.1 ng/ml GM-CSF -57.6%, 10 ng/ ml IL-3 -52.9%, 10 ng/ml TNF -74.8%, GM-CSF þ TNF -81.9%, IL-3 þ TNF -76.3%. Data are from a representative independent experiment performed at least two other times with similar findings and R2-TNF together had no increase in effects above R1-TNF or wild-type TNF alone (data not shown).
Control of life/death switching by cycloheximide
Although addition of GM-CSF or IL-3 increased the susceptibility of TF-1 cells to TNF-induced apoptosis, the proliferative effect of these cytokines predominated and resulted in an increase in total cell number even in the presence of TNF ( Figure 7 ). In order to overcome the proliferative effect of the growth factors, the cells were treated with the protein translation inhibitor cycloheximide in addition to growth factors and TNF. Cycloheximide alone had no effect on the expression of TNFR2 (data not shown) and did not affect the increase in TNFR2 expression caused by GM-CSF or IL-3 ( Figures 8a and b) . Moreover, cycloheximide added alone had no effect on quiescent cells, but decreased the total cell number in the proliferating cells (Figure 8c ). Cycloheximide (1 mg/ml) almost totally abolished the proliferative effect of the cytokines and caused a toxic effect when added in conjunction with TNF ( Figure 7) . However, addition of GM-CSF or IL-3 plus TNF and cycloheximide showed no increase in toxicity above TNF and cycloheximide added together ( Figure 7) . Thus, cycloheximide blocks the proliferative effects of GM-CSF and IL-3 and switches TNF into a more cytotoxic agent, probably by still allowing increased levels of TNFR2 to develop in treated TF-1 cells.
TNF life/death switching in other human leukaemia cells
We tested other types of human leukaemia cells to observe whether they also underwent switching from a proliferative to a cytotoxic phenotype under the control of GM-CSF. As can be seen in Figure 4 TNFR levels of TF-1 cells treated with GM-CSF and IL-3. TNFR levels of TF-1 cells were measured using monoclonal antibodies to TNFR1 (htr-1) and TNFR2 (utr-9). (a) Cells cultured in medium without GM-CSF had similar levels of TNFR1 and TNFR2. A control antibody (mitogen-activated protein kinase, Santa Cruz Biotechnology) gave the same results as no antibody (Ab). Addition of (b) 0.1 ng/ml GM-CSF or (c) 10 ng/ml IL-3 for 24 h increased the surface expression of TNFR2. Data are from a representative independent experiment performed at least two other times with similar findings by side effects including septic shock-like symptoms and widespread inflammation. TNF acts through binding to two different receptor types, which differ in their intracellular signalling pathways and consequent effects. TNFR1 is generally believed to be responsible for many of the deleterious effects of TNF treatment, while less is known about the effects of TNFR2. Altering the TNFR1 : TNFR2 ratio may control the functional outcome of the cell after TNF binding. It was, therefore, hoped that by increasing the expression of TNFR2, the susceptibility of tumour cells to apoptosis would be increased, while reducing the deleterious effects thought to be mediated through TNFR1. Here, we have shown in certain cell types that a TNF life/death switching phenomenon occurs and the fact that these cell types are cancerous leads us to suggest that it may be possible to influence some types of cancer cells. Whether more cancer cell types also perform this life/death switching act or whether non-neoplastic cells also display this phenomenon is something that will require further investigation. However, as a strategy for the greater control of apoptotic and proliferative responses in certain subtypes of cells, the TNF life/death switching we describe here is interesting both from an academic or a therapeutic viewpoint.
TF-1 cells are human erythroleukaemic progenitor stem cells line that are stimulated by GM-CSF or IL-3. 29 GM-CSF and IL-3 promote the survival and stimulate proliferation of haematopoietic cells 30 and we have shown that these cytokines also had a stimulatory effect on quiescent TF-1 cells, but had no additional effect on proliferating cells. Using propidium iodide staining of hypodiploid cells and measurement of the inactive fragment of PARP DNA repair enzyme, both indicators of apoptosis, we also showed that these cytokines were antiapoptotic, as has previously been demonstrated in a variety of haematopoietic cell types. [30] [31] [32] TNF also had a stimulatory effect on quiescent cells and this may have been due to TNF-induced synthesis of GM-CSF, 33 which then acts in an autocrine manner to enhance proliferation. 34 It is presently not clear whether just proliferation and increased TNFR2 expression in TF-1 and K562 cells is sufficient for them to be able to experience TNF life/death switching. It may be that TNF is inducing a factor other than GM-CSF to cause proliferation, a process that is sensitive to cycloheximide (Figure 8 ), although importantly HL-60 cells proliferate in response to GM-CSF ( Figure 10 ) but do not then switch their TNF-responsive phenotype, suggesting a direct TNF effect on the proliferative and apoptotic machinery of cells that are able to switch. It has been demonstrated that the stimulatory effect of TNF is mediated predominantly by TNFR1, whereas TNFR2 produced only minimal proliferation. 34 This was also demonstrated using TNFR-selective agents, with only TNFR1 having a similar stimulatory effect to TNF. Such an apoptotic role for TNFR2 and its lack of involvement in the proliferative effects of TNF is against some of the current thinking, which suggests that TNFR1 is purely apoptotic in nature and TNFR2 acts only to cause proliferation. Here, we see that there is a role for TNFR2 in the life/ death switching phenomenon in these cells and is certainly co-operative in purpose although understanding its exact nature will require further investigation.
We have shown that GM-CSF and IL-3 enhanced the ability of TNF to induce apoptosis. As these growth factors induce proliferation in the quiescent cells, it was possible that this explained the increased susceptibility to TNF-induced apoptosis. However, previous studies have shown that using cytokines to recruit leukaemia cells into cell cycle, and thus Figure 6 Effect of TNFR-selective muteins compared to TNF. When added to proliferating TF-1 cells (cultured in GM-CSF-containing medium), TNF and R1-TNF (10 ng/ml) caused (a) an increase in apoptosis, according to propidium iodide staining, and (b) a similar increase in cytotoxicity, according to the MTS assay. R2-TNF mutein (10 ng/ml) had little or no effect on either apoptosis, cytotoxicity or proliferation Figure 7 Proliferation of TF-1 cells by cytokines and cycloheximide. Cells cultured in medium without GM-CSF were exposed to combinations of GM-CSF (0.1 ng/ml), IL-3 (10 ng/ml), TNF (10 ng/ml) and cycloheximide (1 mg/ml). After 24 h exposure, cells were assayed for metabolic activity (related to viable cell number) using the MTS assay. Data are the mean7S.D. of quadruplicate determinations from a representative independent experiment, repeated at least two other times with similar findings Figure 8 Effect of cycloheximide on TF-1 cells. Cells cultured in medium without GM-CSF were exposed to (a) GM-CSF (0.1 ng/ml) or (b) IL-3 (10 ng/ml), with or without simultaneous addition of cycloheximide (1 mg/ml). After 24 h exposure, the level of TNFR expression was measured and analysed by FACS. The increase in TNFR2 induced by GM-CSF or IL-3 was unaffected by cycloheximide (GM-CSF/IL-3 alone is underneath thick line). Data are from a representative independent experiment performed at least two other times with similar findings. (c) Cells cultured in medium with (closed symbols) and without (open symbols) GM-CSF (proliferating and quiescent cells, respectively) were exposed to cycloheximide at the indicated concentration and viable cell number was measured using the MTS assay. Quiescent cells were unaffected by concentrations up to 1 mg/ml, whereas the total number of proliferating cells was decreased make them more susceptible to chemotherapy, have revealed no benefit and it has been suggested that IL-3 and GM-CSF may even protect cells in vitro from chemotherapy-induced agents. 28 We have also shown that other cytokines (IL-1b and IFN-g), which have stimulatory effects on quiescent TF-1 cells, had no effect on TNF-induced apoptosis. These latter cytokines had little or no effect on the expression of either TNF receptor, whereas GM-CSF and IL-3 both increased the expression of TNFR2, but not TNFR1, as has also been previously demonstrated. 8, 27 It is therefore possible that the increased levels of TNFR2 may be responsible for the increased susceptibility to apoptosis.
It has been demonstrated that TNF-induced apoptosis was mimicked by a TNFR1-stimulating antibody, and was almost completely blocked by a TNFR1-blocking antisera, whereas anti-TNFR2 antisera had only a marginal effect. 21, 35 Selective activation of TNFR1 also elicited a full cytotoxic response in leukaemia cells, 36 and apoptotic response in primary cytotrophoblasts. 37 TNFR2 had little effect in both of these cell types. Berger et al. 17 also showed that TNF-induced apoptosis was mediated preferentially by TNFR1 and suggested that upregulation of TNFR1 expression may be a mechanism for sensitising tumour cells to the effects of TNF leading to haemorrhagic necrosis. Similarly, we have demonstrated here that the TNFR1-specific stimulation had an almost identical toxic effect on proliferating cells to TNF, whereas stimulation of TNFR2 alone had little or no effect ( Figure 6 ). However, wild-type TNF appeared to have a greater effect than R1-TNF in inducing apoptosis (according to propidium iodide staining), with R2-TNF again having no effect. This may indicate that the full apoptotic effect of TNF required stimulation of both TNFR1 and TNFR2. Although TNFR2 alone may not able to induce any effect, it may enhance the effects and signalling of TNFR1. TNFR1-specific muteins, but not TNFR2-specific muteins have also been shown to induce NF-kB activation. 38, 39 Whereas both soluble and membrane-bound TNF have comparable bioactivities when acting on TNFR1, membrane-bound TNF is the prime activating ligand for TNFR2. 40 The membrane-bound form of TNF can also trigger effective cytotoxicity by stimulating TNFR2. 41 It is therefore likely that the effect of TNFR2 activation has been experimentally underestimated here and in other systems.
Although it has been suggested that proapoptotic signals are mediated via TNFR1 and antiapoptotic signals are mediated via TNFR2 in dendritic cells, 42 under certain circumstances the two classes of TNF receptors cooperate with each other to produce enhanced cellular responses. It is possible that TNFR2 may enhance TNFR1-induced apoptosis 43 and it has also been shown that induced TNFR2 expression in the presence of membrane-bound TNF and TNFR1 results in lymphocyte cell death. 44 TNFR2 may also induce toxicity in some cell types as well as potentiating TNFR1-mediated toxic responses. [45] [46] [47] Overexpression of TNFR2 can result in the enhancement of TNFR1-mediated signalling. 48 When overexpressed, TNFR2 can mediate apoptosis, NF-kB activation and c-Jun N-terminal kinase (JNK) activation, 47, 49 whereas TNFR1 can mediate similar signals without overexpression. 6 Thus, although TNFR1 is clearly the primary receptor for TNF's apoptotic responses, TNFR2 may have an ancillary role to modulate TNFR1's actions. This is also supported here in the evidence that TF-1 and K562 cells require effective activity in order for both the proliferative and apoptotic effects of TNF to become apparent as incubation with an anti-TNFR antisera blocks TNF responses in these cell types. Blockade of TNFR2 with A potential ligand-passing role for TNFR2 was proposed by Tartaglia et al, 50 in which TNFR2 acts to bind TNF with high affinity and increase the local microenvironment of TNF ligand surrounding the TNFR1 receptor, which then activates intracellular apoptotic signalling. Heterocomplexes of TNFR1 and TNFR2 have been observed which support such a ligandpassing mode of TNFR2 function. 51 Such a ligand-passing role for TNFR2 may be responsible here in the observed enhancement of TNF-stimulated apoptosis in GM-CSFswitched TF-1 cells, since raised TNFR2 levels correlate with the apoptotic phenotype, but TNFR2 stimulation by itself does not mediate cell death. However, the function of TNFR2 is necessary in TF-1 and K562 cell TNF life/death responses as shown here with antagonistic antisera. This again supports a possible ligand-passing role of TNFR2 in life/death switching. However, the cooperativity of TNFR1 and TNFR2 in life/death switching may occur not at the level of the ligand but at the level of their intracellular signalling, as has been suggested by others. 48, [51] [52] [53] [54] The notion of ligand-passing by TNFR2 seems to be less favoured now by researchers and clearly more work needs to be performed to properly understand the mechanisms of TNFR2-enhancement of TNFR1 responses.
Stimulation of TNFR1 can trigger such opposing cellular responses as antiapoptotic NF-kB activation and induction of apoptosis within the same cell. 52 Activation of the transcription factor NF-kB, and subsequent induction of protective proteins, is involved in TNF-induced cell survival 55 and can protect against TNF-induced apoptosis. Thus, it has been proposed that the balance between life and death is regulated by NF-kB. 25 The pathway which is initially chosen may depend on the presence or absence of low constitutive NF-kB activation. Inhibition of the induction of NF-kB sensitises cells to TNF-induced toxicity, 56 and inhibition of protein synthesis appears to have a similar effect. We have shown that the protein-synthesis inhibitor, cycloheximide, sensitised TF-1 cells to TNF-induced toxicity, and this was most likely by preventing induction of protective or survival factors. 57 Unlike the proliferative responses, TF-1 apoptosis probably does not require protein synthesis as apoptosis occurred in the presence of cycloheximide ( Figure 6 ). Moreover, GM-CSF or IL-3 induction of TNFR2 still persisted with cycloheximide present. It may be that TNFR2 induction may be less sensitive to cycloheximide or that there is a presynthesised pool of TNFR2 that is unaffected by cycloheximide that is still exhibited through GM-CSF or IL-3 treatment. Either way, cycloheximide allowed only the apoptotic responses of TNF to be demonstrated. It may also be that instead of GM-CSF or IL-3 causing the switching from a proliferative to a death phenotype, TNF-induced proliferation may still occur after GM-CSF pretreatment, but GM-CSF may signal a TNFapoptotic pathway to be revealed that outweighs any TNF proliferative responses.
Materials and Methods

Materials
All tissue culture reagents were from Invitrogen Ltd., Paisley, UK. Recombinant human cytokines were purchased from R&D Systems, Abingdon, UK. GM-CSF was a generous gift from Dr. Meenu Wadhwa (NIBSC, Potter's Bar, UK). TNFR1-and TNFR2-selective mutant proteins ('muteins') R1-TNF and R2-TNF, respectively, were as previously described. 8, 58 TNFR monoclonal antisera htr-9 (TNFR1) and utr-1 (TNFR2) were from Bachem Ltd., Merseyside, UK. Antagonistic monoclonal TNFR2-specific antisera (Genzyme Corporation) was as described previously. 8 All other reagents were purchased from SigmaAldrich Company, Dorset, UK and were of the highest grade available.
Cells
TF-1 human erythroleukaemic cells were purchased from ECACC (cell no. 93022307). Cultures of TF-1 cells were maintained in RPMI 1640 medium containing 100 U/ml penicillin, 100 mg/ml streptomycin, 5% foetal bovine serum (FBS) and 0.1 ng/ml human recombinant GM-CSF. Cells were Values represent the means7S.E.M. of at least three independent determinations. All values are normalised to the control cell levels seen in cells in GM-CSFfree conditions, so as to indicate the effect of the GM-CSF-preincubation step on relative cell numbers washed and resuspended in medium with or without GM-CSF, counted and plated onto 96-well plates at a density of 2 Â 10 5 cells/ml or 12-well plates at 1 Â 10 5 cells/ml. Plates were incubated overnight in a gas phase of 5% CO 2 at 371C before adding cytokines. K562 human chronic myelogenous leukaemia cells, MOLT-4 human acute T-lymphocytic leukaemia cells and HL-60 human promyelocytic leukaemia cells were generously donated by Dr. Heather Wallace (University of Aberdeen) and were cultured as for TF-1 cells except that their RPMI 1640 medium was not supplemented with GM-CSF.
TNFR expression measurement
Cells were washed and then resuspended in serum-free medium. A 200 ml aliquot was incubated on ice for 1 h in a 1 : 50 dilution of mouse antihuman TNFR1 or TNFR2 primary antibody (or neither for control assessments). Cells were centrifuged (1000 Â g, 5 min) and then resuspended again in 200 ml serum-free medium with a 1 : 50 dilution of fluorescein isothiocyanate (FITC)-labelled anti-mouse antibody (Diagnostics Scotland, Edinburgh, UK) for 30 min on ice. Prior to fluorescenceactivated cell sorting (FACS) analysis, the cells were washed three times in PBS þ 2% FBS. FACS analysis was performed on a Becton Dickinson FACScaliber according to the manufacturer's protocols.
MTS cytotoxicity/proliferation assay
Cytokines were added to TF-1 cells in 96-well plates and incubated for 4 or 24 h. After this period, 40 ml CellTiter 96 s Aqueous One Solution (MTS; Promega, Southampton, UK) was added to each well and incubated at 371C for 1 h before measuring the absorbance at 540 nm on a Molecular Devices platereader, blanking on a cell-free well.
Apoptosis assays
Propidium iodide staining
Cells in 12-well plates were incubated with cytokines for 4 or 24 h. The cells were then washed with phosphat-buffered saline (PBS) and fixed with 70% ethanol. Propidium iodide (10 mg/ml) and RNase (1 mg/ml) were added to cells and incubated at room temperature for 30 min. Cells were washed again with PBS and the cells analysed by FACS for measurement of cell cycle and DNA hypodiploidicy and fragmentation.
Annexin V Binding
Cells were washed with PBS and resuspended in binding buffer and Annexin V (Caltag MedSystems, Towcester, UK) in the dark for 10 min. Cells were then washed with PBS and resuspended in PBS for FACS analysis.
PARP fragment assay
Cells were washed twice with 1% FBS in PBS and fixed for 10 min in 4% paraformaledhyde in PBS. Cells were washed in PBS containing 0.1% sodium azide and 1% FBS, then twice with PBS containing 0.1% sodium azide, 1% FBS and 0.1% saponin (ICPerm). Cells were resuspended in ICPerm with FITC-labelled 85 kDa PARP fragment antibody (BioSource International, Belgium) for 30 min on ice. Cells were washed twice with ICPerm and once with PBS before resuspending in PBS for FACS analysis.
